| 1 | 10014 | LAO-11030 | ETCTN | Hematopoietic Neoplasm (excluding Leukemia, Lymphoma and Myeloma);Miscellaneous and Metastatic Cancer | Active | A Pilot Study of Atezolizumab (MPDL3280A) Following Adoptive Cell Transfer in Active Hematologic or Solid Tumor Malignancies | Pilot | 22/40 | N/A | INTERVENTION |
| 2 | 10026 | LAO-MA036 | ETCTN | Leukemia | Active | A Phase 1 Study of Ipilimumab in Combination with Decitabine in Relapsed or Refractory Myelodysplastic Syndrome/Acute Myeloid Leukemia | I | 50/48 | N/A | INTERVENTION |
| 3 | 10057 | LAO-MA036 | ETCTN | Female Reproductive System Cancer;Lymphoma;Skin Cancer | Active | A Phase II Study of Talimogene Laherparepvec Followed by Talimogene Laherparepvec + Nivolumab in Refractory T Cell and NK Cell Lymphomas, Cutaneous Squamous Cell Carcinoma, Merkel Cell Carcinoma, and Other Rare Skin Tumors | II | 45/68 | N/A | INTERVENTION |
| 4 | 10170 | LAO-CT018 | ETCTN | Kidney Cancer;Miscellaneous and Metastatic Cancer | Active | A Phase 2 Study of AZD1775 in SETD2-Deficient Advanced Solid Tumor Malignancies | II | 15/60 | N/A | INTERVENTION |
| 5 | 10184 | LAO-NCI | ETCTN | Head and Neck Cancer | Active | Birinapant and Intensity Modulated Re-Irradiation Therapy (IMRRT) for Locoregionally Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC) | I | 1/34 | N/A | INTERVENTION |
| 6 | 10216 | LAO-OH007 | ETCTN | Lung, Mediastinal, and Pleural Cancer | Active | A Phase I/II Study of AZD9291 (Osimertinib) and CB-839 HCl in Patients with EGFR Mutant Non-Small Cell Lung Cancer | I/II | 7/18 | N/A | INTERVENTION |
| 7 | 10264 | LAO-CT018 | ETCTN | Leukemia | Active | The PRIME Trial: PARP Inhibition in IDH Mutant Effectiveness Trial. A Phase II Study of Olaparib in Isocitrate Dehydrogenase (IDH) Mutant Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome | II | 5/94 | 5 | SCREENING,INTERVENTION |
| 8 | 10273 | LAO-CA043 | ETCTN | Leukemia | Active | A Phase I Study of M3814 in Combination with MEC in Patients with Relapsed or Refractory Acute Myeloid Leukemia | I | 6/48 | N/A | INTERVENTION |
| 9 | 10276 | LAO-11030 | ETCTN | Gastrointestinal Cancer;Miscellaneous and Metastatic Cancer | Active | A Phase I/II Study of M3814 and Avelumab in Combination with Hypofractionated Radiation in Patients with Advanced/Metastatic Solid Tumors and Hepatobiliary Malignancies | I/II | 8/30 | N/A | INTERVENTION |
| 10 | 10296 | LAO-TX035 | ETCTN | Breast Cancer | Active | Phase Ib/II Trial of Copanlisib in Combination with Trastuzumab and Pertuzumab After Induction Treatment of HER2 Positive (HER2+) Metastatic Breast Cancer (MBC) with PIK3CA Mutation or PTEN Mutation | I/II | 0/12 | N/A | INTERVENTION |
| 11 | 10300 | LAO-CT018 | ETCTN | Leukemia | Temporarily Closed to Accrual | BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 1 (BLAST MRD AML-1): A Randomized Phase 2 Study of the Anti-PD-1 Antibody Pembrolizumab in Combination with Conventional Intensive Chemotherapy as Frontline Therapy in Patients with Acute Myeloid Leukemia | II | 0/124 | N/A | INTERVENTION |
| 12 | 10301 | LAO-CT018 | ETCTN | Male Reproductive System Cancer | Active | A Phase I and Randomized Phase II Trial of Radium-223 Dichloride, M3814, & Avelumab in Advanced Metastatic Castrate-Resistant Prostate Cancer (mCRPC) | I/II | 3/24 | N/A | INTERVENTION |
| 13 | 10315 | LAO-CT018 | ETCTN | Endocrine Cancer | Active | A Phase 2 Study of XL184 (Cabozantinib) in Combination with Nivolumab and Ipilimumab for the Treatment of Poorly Differentiated Neuroendocrine Carcinomas | II | 7/30 | N/A | INTERVENTION |
| 14 | 10334 | LAO-CT018 | ETCTN | Leukemia | Temporarily Closed to Accrual | BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 2 (BLAST MRD AML-2): A Randomized Phase 2 Study of the Venetoclax, Azacitadine, and Pembrolizumab (VAP) Versus Venetoclax and Azacitadine as First Line Therapy in Older Patients with Acute Myeloid Leukemia (AML) Who Are Ineligible or Who Refuse Intensive Chemotherapy | II | 0/76 | N/A | INTERVENTION |
| 15 | 9892 | LAO-PA015 | ETCTN | AIDS-related Malignancy and Condition;Female Reproductive System Cancer | Active | Phase I Dose-Escalation Bioavailability Study of Oral Triapine in Combination with Concurrent Chemoradiation for Locally Advanced Cervical Cancer (LACC) and Vaginal Cancer | I | 5/64 | N/A | INTERVENTION |
| 16 | 9950 | LAO-MD017 | ETCTN | Head and Neck Cancer | Active | A Phase I Study of M6620 (VX-970) in Combination with Cisplatin and XRT in Patients with Locally Advanced Head and Neck Squamous Cell Carcinoma (HNSCC; SDC 10060121) | I | 28/45 | N/A | INTERVENTION |
| 17 | 9979 | LAO-MD017 | ETCTN | Miscellaneous and Metastatic Cancer | Active | Phase 1 and Pharmacology Study of Oral 5-Iodo-2-Pyrimidinone-2-Deoxyribose (IPdR) as a Prodrug for IUdR-Mediated Tumor Radiosensitization in Brain Metastases | I | 9/47 | N/A | INTERVENTION |
| 18 | A041501 | ALLIANCE | NCTN | Leukemia | Active | A Phase III Trial to Evaluate the Efficacy of the Addition of Inotuzumab Ozogamicin (a Conjugated Anti-CD22 Monoclonal Antibody) to Frontline Therapy in Young Adults (Ages 18-39 Years) with Newly Diagnosed Precursor B-Cell ALL | III | 162/341 | N/A | INTERVENTION |
| 19 | A041703 | ALLIANCE | NCTN | Leukemia | Active | A Phase II Study of Inotuzumab Ozogamicin Followed by Blinatumomab for Ph-Negative, CD22-Positive B-Lineage Acute Lymphoblastic Leukemia in Newly Diagnosed Older Adults or Adults with Relapsed or Refractory Disease | II | 24/64 | N/A | INTERVENTION |
| 20 | A171901 | ALLIANCE | NCORP | Lung, Mediastinal, and Pleural Cancer | Active | Older Non-Small Cell Lung Cancer Patients (>/= 70 Years of Age) Treated with First-Line MK-3475 (Pembrolizumab)+/- Chemotherapy (Oncologist's/Patient's Choice) | II | 3/100 | N/A | INTERVENTION |
| 21 | A221702 | ALLIANCE | NCORP | Breast Cancer | Active | ARM: Axillary Reverse Mapping - A Prospective Trial to Study Rates of Lymphedema and Regional Recurrence after Sentinel Lymph Node Biopsy and Sentinel Lymph Node Biopsy Followed by Axillary Lymph Node Dissection with and without Axillary Reverse Mapping | III | 177/516 | N/A | INTERVENTION |
| 22 | DCP-001 | DCP | NCORP | Hematopoietic Neoplasm (excluding Leukemia, Lymphoma and Myeloma);Miscellaneous and Metastatic Cancer | Active | Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP) | Other | N/A | N/A | OTHER |
| 23 | EA1181 | ECOG-ACRIN | NCTN | Breast Cancer | Active | EA1181 (CompassHER2-pCR): Preoperative THP and Postoperative HP in Patients Who Achieve a Pathologic Complete Response Part 1 Component of: The CompassHER2 Trials (COMprehensive Use of Pathologic Response ASSessment to Optimize Therapy in HER2-Positive Breast Cancer) | II | 225/1250 | N/A | INTERVENTION |
| 24 | EA2182 | ECOG-ACRIN | NCTN | Gastrointestinal Cancer | Active | A Randomized Phase II Study of De-Intensified ChemoRadiation for Early-Stage Anal Squamous Cell Carcinoma (DECREASE) | II | 23/252 | 23 | SCREENING,INTERVENTION |
| 25 | EA5163 | ECOG-ACRIN | NCTN | Lung, Mediastinal, and Pleural Cancer | Active | EA5163/S1709 INSIGNA : A Randomized, Phase III Study of Firstline Immunotherapy Alone or in Combination with Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) with Immunobiomarker SIGNature-Driven Analysis | III | 260/846 | N/A | INTERVENTION |
| 26 | EA6141 | ECOG-ACRIN | NCTN | Skin Cancer | Active | Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma | II/III | 268/600 | N/A | INTERVENTION |
| 27 | EA8134 | ECOG-ACRIN | NCTN | Male Reproductive System Cancer | Active | InPACT- International Penile Advanced Cancer Trial (International Rare Cancers Initiative Study) | III | 41/200 | N/A | INTERVENTION |
| 28 | EA9181 | ECOG-ACRIN | NCTN | Leukemia | Active | A Phase III Randomized Trial of Steroids + Tyrosine Kinase Inhibitor Induction with Chemotherapy or Blinatumomab for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults | III | 0/348 | 0 | SCREENING,INTERVENTION |
| 29 | EAA173 | ECOG-ACRIN | NCTN | Myeloma | Active | Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM) | III | 65/288 | N/A | INTERVENTION |
| 30 | EAY131 | ECOG-ACRIN | NCTN | Lymphoma;Miscellaneous and Metastatic Cancer;Myeloma | Active | Molecular Analysis for Therapy Choice (MATCH) | II | 1153/1425 | 7065 | SCREENING,INTERVENTION |
| 31 | LUNGMAP | SWOG | NCTN | Lung, Mediastinal, and Pleural Cancer | Active | A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screening Study) | II | N/A | 1812 | SCREENING |
| 32 | NRG-BN007 | NRG | NCTN | CNS Cancer (Primary tumor) | Active | A Randomized Phase II/III Open-Label Study of Ipilimumab and Nivolumab Versus Temozolomide in Patients with Newly Diagnosed MGMT (Tumor O-6-Methylguanine DNA Methyltransferase) Unmethylated Glioblastoma | II/III | 19/485 | 38 | SCREENING,INTERVENTION |
| 33 | NRG-BR005 | NRG | NCTN | Breast Cancer | Temporarily Closed to Accrual | A Phase II Trial Assessing the Accuracy of Tumor Bed Biopsies in Predicting Pathologic Response in Patients with Clinical/Radiologic Complete Response After Neoadjuvant Chemotherapy in Order to Explore the Feasibility of Breast Conserving Treatment Without Surgery | II | 105/175 | N/A | INTERVENTION |
| 34 | NRG-GY020 | NRG | NCTN | Female Reproductive System Cancer | Active | A Phase III Randomized Trial of Radiation +/- Pembrolizumab (MK-3475) for Newly Diagnosed Early Stage High Intermediate Risk Mismatch Repair Deficient (dMMR) Endometrioid Endometrial Cancer | III | 31/168 | N/A | INTERVENTION |
| 35 | NRG-GY022 | NRG | NCTN | Miscellaneous and Metastatic Cancer | Active | Assessment of Carboplatin Clearance Predictors: A PK Study on NCI-Sponsored Clinical Trials or Standard of Care Treatments Using Carboplatin | I | 85/250 | N/A | INTERVENTION |
| 36 | PBTC-051 | PBTC | MISCELLANEOUS | CNS Cancer (Primary tumor) | Active | Phase I Study to Evaluate the Safety and Tolerability of the CD40 Agonistic Monoclonal Antibody APX005M in Pediatric Subjects with Recurrent/Refractory Brain Tumors and Newly Diagnosed Brain Stem Glioma | I | 23/45 | N/A | INTERVENTION |
| 37 | S0820 | SWOG | NCORP | Gastrointestinal Cancer | Active | A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients with Stage 0-III Colon or Rectal Cancer, Phase III- Preventing Adenomas of the Colon with Eflornithine and Sulindac (PACES) | III | 306/491 | N/A | INTERVENTION |
| 38 | S1613 | SWOG | NCTN | Gastrointestinal Cancer | Active | A Randomized Phase II Study of Trastuzumab and Pertuzumab (TP) Compared to Cetuximab and Irinotecan (CETIRI) in Advanced/Metastatic Colorectal Cancer (MCRC) with HER-2 Amplification | II | 39/122 | 207 | SCREENING,INTERVENTION |
| 39 | S1712 | SWOG | NCTN | Leukemia | Active | A Randomized Phase II Study of Ruxolitinib (NSC-752295) in Combination with BCR-ABL Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia (CML) Patients with Molecular Evidence of Disease | II | 47/84 | N/A | INTERVENTION |
| 40 | S1914 | SWOG | NCTN | Lung, Mediastinal, and Pleural Cancer | Active | A Randomized Phase III Trial of Induction/Consolidation Atezolizumab (NSC #783608) + SBRT Versus SBRT Alone in High Risk, Early Stage NSCLC | III | 8/480 | N/A | INTERVENTION |
| 41 | S1933 | SWOG | NCTN | Lung, Mediastinal, and Pleural Cancer | Active | A Pilot Study of Hypofractionated Radiotherapy Followed by Atezolizumab Consolidation in Stage II or III NSCLC Patients with Borderline Performance Status | II | 1/47 | N/A | INTERVENTION |
| 42 | 10058 | LAO-TX035 | ETCTN | Gastrointestinal Cancer | Active | A Phase I Study of Talimogene Laherparepvec (TALIMOGENE LAHERPAREPVEC) with Neoadjuvant Chemotherapy and Radiation in Adenocarcinoma of the Rectum | I | 3/21 | N/A | INTERVENTION |
| 43 | 10070 | LAO-MD017 | ETCTN | Lung, Mediastinal, and Pleural Cancer;Miscellaneous and Metastatic Cancer | Active | Phase 1/2 Study of Navitoclax Plus Vistusertib in Patients with Relapsed Small Cell Lung Cancer (SCLC) and Other Solid Tumors | I/II | 14/24 | N/A | INTERVENTION |
| 44 | 10076 | LAO-TX035 | ETCTN | Myeloma | Active | A Phase 1 Dose-Escalation and Exploratory Dose Expansion Study of KRT-232 (AMG 232) in Combination with Carfilzomib, Lenalidomide, and Dexamethasone in Relapsed and/or Refractory Myeloma | I | 9/40 | N/A | INTERVENTION |
| 45 | 10104 | LAO-11030 | ETCTN | Female Reproductive System Cancer | Temporarily Closed to Accrual | A Randomized Phase 2 Study of Cabozantinib in Combination with Nivolumab in Advanced, Recurrent Metastatic Endometrial Cancer | II | 82/84 | N/A | INTERVENTION |
| 46 | 10146 | LAO-CT018 | ETCTN | Breast Cancer | Active | Randomized Phase 2 Clinical Trial of Nab-Paclitaxel + MEDI4736 (Durvalumab) + Tremelimumab + Neoantigen Vaccine Vs. Nab-Paclitaxel + MEDI4736 (Durvalumab) + Tremelimumab in Patients with Metastatic Triple Negative Breast Cancer | II | 0/70 | N/A | INTERVENTION |
| 47 | 10150 | LAO-11030 | ETCTN | Female Reproductive System Cancer | Active | A Randomized Phase 2 Study of Bevacizumab and Either Weekly Anetumab Ravtansine or Weekly Paclitaxel in Platinum-Resistant or Platinum Refractory Ovarian Cancer | I/II | 42/96 | N/A | INTERVENTION |
| 48 | 10183 | EDDO-IL036 | ETCTN | Urothelial/ Bladder Cancer | Active | A Pilot Study of Tazemetostat and Pembrolizumab (MK-3475) in Advanced Urothelial Carcinoma | I/II | 7/30 | N/A | INTERVENTION |
| 49 | 10204 | LAO-TX035 | ETCTN | Hematopoietic Neoplasm (excluding Leukemia, Lymphoma and Myeloma);Miscellaneous and Metastatic Cancer | Active | A Phase Ib Study of Nivolumab in Patients with Autoimmune Disorders and Advanced Malignancies (AIM-NIVO) | I | 13/312 | N/A | INTERVENTION |
| 50 | 10272 | NCICCR | MISCELLANEOUS | Male Reproductive System Cancer | Active | A Phase II Multi-Institutional Trial to Evaluate Prostate Specific Membrane Antigen (PSMA)-Based PET Imaging of High Risk Prostate Cancer | II | 13/200 | N/A | INTERVENTION |